Atezolizumab 840mg/14ml solution for infusion vials
NHS hospitals in England used £21,617,287 of indicative cost of Atezolizumab 840mg/14ml solution for infusion vials in the 12 months to April 2026, about 0.1% of all hospital medicines spend. That is down 14.6% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Atezolizumab 840mg/14ml solution for infusion vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Atezolizumab 840mg/14ml solution for infusion vials most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Sheffield Teaching Hospitals Nhs Trust | £1,620,551 |
| The Christie Nhs Foundation Trust | £1,513,936 |
| Barts Health Nhs Trust | £1,359,344 |
| The Clatterbridge Cancer Centre Nhs Ft | £1,244,732 |
| United Lincolnshire Hospitals Nhs Trust | £1,026,171 |
| University Hpls North Midlands Nhs Trust | £802,279 |
| Nottingham University Hospitals Trust | £780,956 |
| Univ Hpl B/Ham Nhs Foundation Trust | £706,326 |
| Mid Yorkshire Hospitals Nhs Trust | £690,333 |
| Western Sussex Hospitals Nhs Found Trust | £573,057 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.